Pharma BD Deal Intelligence
JLL executives believed the fragmented contract manufacturing industry was ripe for a roll-up at a time when pharma was looking for partners with a spectrum of…
DSM characterized the move as a key step in the strategic transformation of its Pharma activities into partnerships, monetizing DPP while retaining 49% upside…
JLL Partners closed the merger forming DPx Holdings, calling it a transformative platform for CDMO consolidation.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
JLL Partners and Royal DSM created DPx Holdings BV (later Patheon NV) by combining DSM Pharmaceutical Products and Patheon in $2.6B transaction; Patheon enterprise value ~$1.98B at $9.32/share.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products (this deal) | 2013 | $2.6B | 90 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| Pamplona Capital Management, LLP / PAREXEL International Corporation | 2017 | $5.0B | 90 |
| Thermo Fisher Scientific Inc. / Patheon N.V. | 2017 | $7.2B | 89 |
← Browse all deals · How we score deals
More: 2013 deals · Other deals